Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?

Immunother Adv · 2023 · PMC10676196 · PMID 38020310

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although in responders, only the CD8+ T cells showed a significant increase in proliferation marker Ki67 following treatment with Pembrolizumab, CD4+ T cells also showed a trend toward increased Ki67 expression, suggesting that PD-1 blockade has a greater impact on CD8+ than CD4+ T cells.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.